Carolyn F. Deacon

Carolyn F. Deacon

Associate Professor


  1. 1995
  2. Published

    Both subcutaneously and intravenously administered glucagon-like peptide-1 are rapidly degraded from the amino terminus in type II diabetic patients and in healthy subjects. / Deacon, C.F.; Nauck, M.A.; Nielsen, M.T.; Pridal, L.; Holst, Jens Juul.

    In: Diabetes, No. 44, 1995, p. 1126-1131.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    Degradation of glucagon-like peptide-1 in vitro yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo. / Deacon, C.F.; Johnsen, A.H.; Holst, Jens Juul.

    In: Journal of Clinical Endocrinology and Metabolism, No. 80, 1995, p. 952-957.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Human colon produces fully processed glucagon-like peptide-1 (7-36 amide). / Deacon, C.F.; Johnsen, A.H.; Holst, Jens Juul.

    In: FEBS Letters, No. 372, 1995, p. 269-272.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. 1996
  6. Published

    Plasma TNF-x is associated with insulin mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy. / Haugaard, S.B.; Andersen, O.; Pedersen, S.B.; Dela, Flemming; Deacon, C.F.

    In: Metabolism - Clinical and Experimental, No. 55(2), 1996, p. 175-182.

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. 1997
  8. Published

    Posttranslational processing of proglucagon and postsecretory fate of proglucagon products. / Holst, Jens Juul; Ørskov, C.; Hartmann, Bolette; Deacon, C.F.

    The Insulinotropic Gut Hormone Glucagon-like Peptide-1.. Basel : Karger, 1997. p. 24-48.

    Research output: Chapter in Book/Report/Conference proceedingBook chapterResearch

  9. 1998
  10. Published

    Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. / Deacon, C.F.; Hughes, T.E.; Holst, J.J.

    In: Diabetes, No. 47, 1998, p. 764-769.

    Research output: Contribution to journalJournal articleResearchpeer-review

  11. Published

    Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. / Deacon, C.F.; Knudsen, L.B.; Madsen, K.; Wiberg, F.C.; Jacobsen, O.; Holst, J.J.

    In: Diabetologia, No. 41, 1998, p. 271-278.

    Research output: Contribution to journalJournal articleResearchpeer-review

  12. Published

    Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. / Holst, J.J.; Deacon, C.F.

    In: Diabetes, No. 47, 1998, p. 1663-1670.

    Research output: Contribution to journalJournal articleResearchpeer-review

  13. Published

    On the treatment of diabetes mellitus with glucagon-like peptide-1. / Holst, J.J.; Deacon, C.F.; Toft-Nielsen, M.; Bjerre-Knudsen, L.

    In: Annals of the New York Academy of Sciences, No. 865, 1998, p. 336-343.

    Research output: Contribution to journalJournal articleResearchpeer-review

  14. 1999
  15. Published

    Glucagon-like peptide-1(7-36)amide is transformed to glucagon-like peptide-1 (9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the intestinal L-cells. / Hansen, L.; Deacon, C.F.; Ørskov, C.; Holst, J.J.

    In: Endokrinologiya, No. 140, 1999, p. 5356-5363.

    Research output: Contribution to journalJournal articleResearchpeer-review

Previous 1 2 3 4 5 6 7 8 ...22 Next

ID: 9220